Fiduciary Trust Co. grew its position in Zoetis Inc. (NYSE:ZTS) by 65.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,148 shares of the company’s stock after acquiring an additional 5,207 shares during the quarter. Fiduciary Trust Co.’s holdings in Zoetis were worth $820,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of ZTS. CGOV Asset Management boosted its holdings in shares of Zoetis by 2.7% in the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock valued at $12,059,000 after acquiring an additional 4,405 shares during the period. Canada Pension Plan Investment Board boosted its holdings in shares of Zoetis by 46,440.1% in the first quarter. Canada Pension Plan Investment Board now owns 143,809 shares of the company’s stock valued at $7,675,000 after acquiring an additional 143,500 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Zoetis during the first quarter worth $112,000. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Zoetis by 14.1% during the first quarter. Commerzbank Aktiengesellschaft FI now owns 9,287 shares of the company’s stock worth $496,000 after purchasing an additional 1,146 shares during the period. Finally, Bbva Compass Bancshares Inc. lifted its holdings in shares of Zoetis by 73.6% during the first quarter. Bbva Compass Bancshares Inc. now owns 5,746 shares of the company’s stock worth $307,000 after purchasing an additional 2,436 shares during the period. 93.20% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently weighed in on ZTS. BidaskClub downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 price target on shares of Zoetis in a report on Wednesday, September 6th. Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price target on shares of Zoetis in a report on Friday, September 1st. Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the stock a “buy” rating in a report on Friday, August 25th. Finally, Cowen and Company set a $70.00 price target on Zoetis and gave the stock a “buy” rating in a report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and an average target price of $65.44.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/fiduciary-trust-co-grows-position-in-zoetis-inc-zts/1603555.html.
Shares of Zoetis Inc. (NYSE:ZTS) opened at 64.16 on Friday. The company’s 50-day moving average price is $62.44 and its 200-day moving average price is $59.64. The stock has a market cap of $31.38 billion, a PE ratio of 36.27 and a beta of 1.02. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $65.83.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting analysts’ consensus estimates of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter last year, the company posted $0.49 earnings per share. Zoetis’s quarterly revenue was up 5.0% on a year-over-year basis. Analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current year.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.